Competing Priorities: Alzheimer's Drugs and the Delicate Balance that Defines Part D

The Alzheimer’s Association waged and won a six-month battle to end prior authorization programs for AD medications in three Medicare plans. The skirmish has big implications for future of Medicare formularies— and the balance of power between Big Pharma and managed care.